New

AI v2.0 Beta Launched. Experience the future of pharmaceutical care.

Try Now
Drug info language
Switches all medical info on this page (labels, indications, leaflet) without changing the rest of the interface.
Highly Regulated (List I)

REBIF

22µG/0,5ML (6MUI/0,5ML)/SC Injectable Solution (Pre-filled Syringe)/INTERFERON BETA 1A
MERCK
ManufacturerVerified lab

MERCK

Public retail price
5802.52DZD

Identification

Active ingredient (INN)
INTERFERON BETA 1A
Internal code
15 G 078
Country of Origin
United Kingdom
Pharmaceutical form
SC Injectable Solution (Pre-filled Syringe)
Prescription List
Highly Regulated (List I)
Packaging
b/12 seringues preremplies de 0.5ml
REBIF
Clinical View
Highly Regulated (List I)

DAWA Clinical Workbench v2.0

Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.

Description

Human interferon beta (166 residues), glycosylated, MW=22.5kD.

It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced.

The amino acid sequence is identical to that of natural human interferon beta.

Indications

For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum

Pharmacodynamics

Interferon beta upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens.

This enhances the activation of

CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing.

I interferons also induce the synthesis of several key antiviral mediators including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin and neopterin.

Mechanism of Action

Interferon alpha/beta receptor 1 Agonist Interferon alpha/beta receptor 2 Agonist.

Adverse Effects

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

Warnings

Stop use and ask doctor if symptoms persist more than 5 days or worsen.

If pregnant or breast-feeding ask a health professional before use.

Keep out of reach of children.

Dosage & Administration

Take 15 minutes before meals Adults and children 12 years and older 5 pellets 3 times per day Children between 12 years and 6 years of age 3 pellets 3 times per day Children under 6 years 1 pellet 3 times per day to be disoolved into a little water.

Alternatives